Inferra AIResearch Tools

Inferra AI / Company / COR

Cencora

COR · Health Care

Last earnings Aug 5, 2026  ·  Next earnings Nov 4, 2026

Key results

Revenuequarter

$80.7 billion

Revenue of $80.7 billion for the Third Quarter, an 8.7 percent Increase Year-Over-Year Third Quarter

SEC original ↗Cencora — Earnings release (8-K exhibit)EX-99Aug 6, 2025

GAAP EPSquarter

$3.52

GAAP Diluted EPS of $3.52 and

SEC original ↗Cencora — Earnings release (8-K exhibit)EX-99Aug 6, 2025

Adjusted EPSquarter

$4.00

Adjusted Diluted EPS of $4.00

SEC original ↗Cencora — Earnings release (8-K exhibit)EX-99Aug 6, 2025

Revenuefull-year

8.7 percent

(NYSE COR) reported that in its fiscal year 2025 third quarter ended June 30, 2025, revenue increased 8.7 percent year-over-year to $80.7 billion.

SEC original ↗Cencora — Earnings release (8-K exhibit)EX-99Aug 6, 2025

EPSquarter

$3.52

generally accepted accounting principles (GAAP), diluted earnings per share (EPS) was $3.52 for the third quarter of fiscal 2025 compared to $2.42 in the prior year third quarter.

SEC original ↗Cencora — Earnings release (8-K exhibit)EX-99Aug 6, 2025

B operating incomequarter

$0.9B

Third Quarter Fiscal Year 2025 Summary Results GAAP Adjusted (Non-GAAP) Revenue $80.7B $80.7B Gross Profit $2.9B $2.9B Operating Expenses $2.0B $1.8B Operating Income $0.9B $1.1B Interest Expense, Net $82M $82M Effective Tax Rate 23.0% 20.7% Net Income Attributable to Cencora, Inc.

SEC original ↗Cencora — Earnings release (8-K exhibit)EX-99Aug 6, 2025

Growthfull-year

up 8.7 percent

Third Quarter GAAP Results Revenue In the third quarter of fiscal 2025, revenue was $80.7 billion, up 8.7 percent compared to the same quarter in the previous fiscal year, due to an 8.5 percent increase in revenue within the U.

SEC original ↗Cencora — Earnings release (8-K exhibit)EX-99Aug 6, 2025

Healthcare Solutions segment and a 10.5 percent increase in revenue within the International Healthcare Solutions segment.

SEC original ↗Cencora — Earnings release (8-K exhibit)EX-99Aug 6, 2025

AI analysis

Q3 FY2025 · reported Aug 6, 2025

Based on: Earnings release + parent 8-K + 10-Q — transcript not held

Revenue · Q3 FY2025
$80.7B
EX-99 · Aug 6, 2025
GAAP EPS · Q3 FY2025
$3.52
+45.5% vs year ago computed from stated figures
EX-99 · Aug 6, 2025
B operating income · Q3 FY2025
$0.9B
EX-99 · Aug 6, 2025
Adjusted EPS · Q3 FY2025
$4.00
EX-99 · Aug 6, 2025

The quarter in charts

Diluted EPS — GAAP

Per diluted share, as stated

01.332.674$2.42Same quarter last year$3.52Q3 FY2025 (quarter)

EX-99 · Aug 6, 2025 EPS values as stated in the release.

Guidance ladder — revenue

Delivered vs the company's guided range

EX-99 · Aug 6, 2025 Guide as stated by the company; range and midpoint computed from the stated figure.

Headline figures

MetricQ3 FY2025Prior qtrYear ago
Revenue$80.7 billion——
GAAP EPS$3.52—$2.42
Adjusted EPS$4.00——
EPS$3.52—$2.42
B operating income$0.9B——

EX-99 · Aug 6, 2025

Guidance · company-stated

Direction: Raised

Revenue$80.7 billion

“htm EX-99.1 Document Exhibit 99.1 CENCORA REPORTS FISCAL 2025 THIRD QUARTER RESULTS Revenue of $80.7 billion for the Third Quarter, an 8.7 percent Increase Year-Over-Year Third Quarter GAAP Diluted EPS of $3.52 and Adjusted Diluted EPS of $4.00 Adjusted Diluted EPS Guidance Range Raised to $15.85 to $16.00 for Fiscal 2025 CONSHOHOCKEN, PA, August 6, 2025 - Cencora, Inc.”

EPS

“Adjusted diluted EPS guidance has been raised from the previous range of $15.70 to $15.95 to a range of $15.85 to $16.00.”

Midpoint vs latest-quarter revenue0.0%computed from stated figures

Classified from the release's primary full-year outlook statement.

Next earningsNov 4, 2026Verified from the company’s own announcement

Capital allocation

Dividend$0.55

Interest Expense, Net In the third quarter of fiscal 2025, net interest expense was $81.8 million, an increase of $50.5 million from the prior year quarter primarily due to an increase in interest expense as a result of our issuance of senior notes and a variable-rate term loan to finance a portion of the January 2025 acquisition of RCA, and increased revolving credit facility borrowings to cover short-term working capital needs.

What changed vs last quarter

  • Guide midpoint vs latest-quarter revenue 0.0% computed from stated figures
General educational research only — not investment advice.Every figure is as stated in the held documents; values marked “computed from stated figures” are arithmetic on those stated figures. Guidance shown is the company’s own stated guidance. No price targets, no recommendations, no consensus estimates.

Event summary

CENCORA REPORTS FISCAL 2025 THIRD QUARTER RESULTS

Based on: Earnings release + parent 8-K + 10-Q — transcript not held

Guidance & outlook

Direction: Raised

Revenue: “htm EX-99.1 Document Exhibit 99.1 CENCORA REPORTS FISCAL 2025 THIRD QUARTER RESULTS Revenue of $80.7 billion for the Third Quarter, an 8.7 percent Increase Year-Over-Year Third Quarter GAAP Diluted EPS of $3.52 and Adjusted Diluted EPS of $4.00 Adjusted Diluted EPS Guidance Range Raised to $15.85 to $16.00 for Fiscal 2025 CONSHOHOCKEN, PA, August 6, 2025 - Cencora, Inc.”

EPS: “Adjusted diluted EPS guidance has been raised from the previous range of $15.70 to $15.95 to a range of $15.85 to $16.00.”

Revenue — Raised (“Increase”)
“htm EX-99.1 Document Exhibit 99.1 CENCORA REPORTS FISCAL 2025 THIRD QUARTER RESULTS Revenue of $80.7 billion for the Third Quarter, an 8.7 percent Increase Year-Over-Year Third Quarter GAAP Diluted EPS of $3.52 and Adjusted Diluted EPS of $4.00 Adjusted Diluted EPS Guidance Range Raised to $15.85 to $16.00 for Fiscal 2025 CONSHOHOCKEN, PA, August 6, 2025 - Cencora, Inc.”

EPS — Raised (“raised”)
“Adjusted diluted EPS guidance has been raised from the previous range of $15.70 to $15.95 to a range of $15.85 to $16.00.”

Classified from the release's primary full-year outlook statement.

Capital allocation

Interest Expense, Net In the third quarter of fiscal 2025, net interest expense was $81.8 million, an increase of $50.5 million from the prior year quarter primarily due to an increase in interest expense as a result of our issuance of senior notes and a variable-rate term loan to finance a portion of the January 2025 acquisition of RCA, and increased revolving credit facility borrowings to cover short-term working capital needs.

SEC original ↗Cencora — Earnings release (8-K exhibit)EX-99Aug 6, 2025

Diluted Shares Outstanding Diluted weighted average shares outstanding for the third quarter of fiscal 2025 were 195.2 million, a decrease of 2.4 percent versus the prior year third quarter primarily due to share repurchases.

SEC original ↗Cencora — Earnings release (8-K exhibit)EX-99Aug 6, 2025

In the third quarter of fiscal 2025, net interest expense was $81.8 million, an increase of $50.5 million from the prior year quarter primarily due to an increase in interest expense as a result of our issuance of senior notes and a variable-rate term loan to finance a portion of the January 2025 acquisition of RCA, and increased revolving credit facility borrowings to cover short-term working capital needs.

SEC original ↗Cencora — Earnings release (8-K exhibit)EX-99Aug 6, 2025

Diluted weighted average shares outstanding for the third quarter of fiscal 2025 were 195.2 million, a decrease of 2.4 percent versus the prior year third quarter primarily due to share repurchases.

SEC original ↗Cencora — Earnings release (8-K exhibit)EX-99Aug 6, 2025

Dividend Declaration The Company s Board of Directors declared a quarterly cash dividend of $0.55 per common share, payable September 3, 2025, to stockholders of record at the close of business on August 15, 2025.

SEC original ↗Cencora — Earnings release (8-K exhibit)EX-99Aug 6, 2025

Adjusted Free Cash Flow Adjusted free cash flow is a non-GAAP financial measure defined as net cash provided by operating activities, excluding significant unpredictable or non-recurring cash payments or receipts relating to legal settlements, minus capital expenditures.

SEC original ↗Cencora — Earnings release (8-K exhibit)EX-99Aug 6, 2025

Strategy & priorities

Cencora delivered strong financial results in the third fiscal quarter, driven by our pharmaceutical-centric strategy and focus on our growth priorities, said Robert P.

SEC original ↗Cencora — Earnings release (8-K exhibit)EX-99Aug 6, 2025

We are guided by our purpose and focused on our strategic drivers of digital transformation, investing in our talent and culture, prioritizing growth-oriented investments and increasing productivity.

SEC original ↗Cencora — Earnings release (8-K exhibit)EX-99Aug 6, 2025

These forward-looking statements may include, without limitation, statements regarding our financial position, business strategy and the plans and objectives of management for our future operations; future liabilities and other obligations; anticipated trends and prospects in the industries in which our business operates; new products, services and related strategies; and capital allocation, including share repurchases and dividends.

SEC original ↗Cencora — 10-Q Quarterly report10-QAug 5, 2026

New Reporting Structure The Company undertook a strategic review of its business to ensure alignment with its growth priorities and strategic drivers.

SEC original ↗Cencora — 10-Q Quarterly report10-QAug 5, 2026

The International Healthcare Solutions reportable segment consists of Alliance Healthcare, Innomar, World Courier, and strategic components of PharmaLex.

SEC original ↗Cencora — 10-Q Quarterly report10-QAug 5, 2026

Risks & headwinds

Gross Profit Gross profit in the third quarter of fiscal 2025 was $2.9 billion, a 20.6 percent increase compared to the same quarter in the previous fiscal year, primarily due to the increase in gross profit in both reportable segments and a LIFO credit in the current year quarter in comparison to LIFO expense in the prior year quarter, offset in part by lower gains from antitrust litigation settlements in the current year quarter.

SEC original ↗Cencora — Earnings release (8-K exhibit)EX-99Aug 6, 2025

These statements are based on management s current expectations and are subject to uncertainty and changes in circumstances and speak only as of the date hereof.

SEC original ↗Cencora — Earnings release (8-K exhibit)EX-99Aug 6, 2025

A more detailed discussion of the risks and uncertainties that could cause our actual results to differ materially from those indicated is included (i) in the Risk Factors and Management's Discussion and Analysis sections in the Company s Annual Report on Form 10-K for the fiscal year ended September 30, 2024 and elsewhere in that report and (ii) in other reports filed by the Company pursuant to the Securities Exchange Act.

SEC original ↗Cencora — Earnings release (8-K exhibit)EX-99Aug 6, 2025

$ 687,402 0.85% $ 483,463 0.65% 42.2% Earnings per share Basic $ 3.55 $ 2.44 45.5% Diluted $ 3.52 $ 2.42 45.5% Weighted average common shares outstanding Basic 193,822 198,260 (2.2)% Diluted 195,230 200,047 (2.4)% ________________________________________ 1 Includes a $9.5 million gain from antitrust litigation settlements, a $52.1 million LIFO credit, and Turkey foreign currency remeasurement expense of $14.8 million in the three months ended June 30, 2025.

SEC original ↗Cencora — Earnings release (8-K exhibit)EX-99Aug 6, 2025

Includes a $51.6 million gain from antitrust litigation settlements, a $6.8 million LIFO expense, and Turkey foreign currency remeasurement expense of $3.6 million in the three months ended June 30, 2024.

SEC original ↗Cencora — Earnings release (8-K exhibit)EX-99Aug 6, 2025

$ 1,893,873 0.80% $ 1,505,738 0.70% 25.8% Earnings per share Basic $ 9.77 $ 7.56 29.2% Diluted $ 9.70 $ 7.49 29.5% Weighted average common shares outstanding Basic 193,794 199,253 (2.7)% Diluted 195,172 201,025 (2.9)% ________________________________________ 1 Includes a $231.0 million gain from antitrust litigation settlements, a $19.9 million LIFO credit, and Turkey foreign currency remeasurement expense of $36.4 million in the nine months ended June 30, 2025.

SEC original ↗Cencora — Earnings release (8-K exhibit)EX-99Aug 6, 2025

Competitors

Competitors & peers

Named in the company’s own filings

McKesson (MCK)“Our largest competitors are McKesson Corporation ( McKesson ), Cardinal Health, Inc.”Cardinal Health (CAH)“Our largest competitors are McKesson Corporation ( McKesson ), Cardinal Health, Inc.”
Documents

Filings

63 documents

Earnings releases

22 documents

Presentations

0 documents

No presentations for Cencora are held in this edition of the library.

Transcripts

0 documents

No transcripts for Cencora are held in this edition of the library.

Mentioned by

9 companies

Other tracked companies whose held documents mention Cencora by name or ticker. A mention is counted once per document, from the document text the library holds.

See also the earnings calendar for every tracked company’s next earnings date.